Gene therapy for aromatic L-amino acid decarboxylase deficiency
- PMID: 22593174
- DOI: 10.1126/scitranslmed.3003640
Gene therapy for aromatic L-amino acid decarboxylase deficiency
Abstract
Aromatic L-amino acid decarboxylase (AADC) is required for the synthesis of the neurotransmitters dopamine and serotonin. Children with defects in the AADC gene show compromised development, particularly in motor function. Drug therapy has only marginal effects on some of the symptoms and does not change early childhood mortality. Here, we performed adeno-associated viral vector-mediated gene transfer of the human AADC gene bilaterally into the putamen of four patients 4 to 6 years of age. All of the patients showed improvements in motor performance: One patient was able to stand 16 months after gene transfer, and the other three patients achieved supported sitting 6 to 15 months after gene transfer. Choreic dyskinesia was observed in all patients, but this resolved after several months. Positron emission tomography revealed increased uptake by the putamen of 6-[(18)F]fluorodopa, a tracer for AADC. Cerebrospinal fluid analysis showed increased dopamine and serotonin levels after gene transfer. Thus, gene therapy targeting primary AADC deficiency is well tolerated and leads to improved motor function.
Similar articles
-
Gene therapy for aromatic L-amino acid decarboxylase deficiency by MR-guided direct delivery of AAV2-AADC to midbrain dopaminergic neurons.Nat Commun. 2021 Jul 12;12(1):4251. doi: 10.1038/s41467-021-24524-8. Nat Commun. 2021. PMID: 34253733 Free PMC article. Clinical Trial.
-
Functional effect of adeno-associated virus mediated gene transfer of aromatic L-amino acid decarboxylase into the striatum of 6-OHDA-lesioned rats.Mol Ther. 2001 Oct;4(4):324-30. doi: 10.1006/mthe.2001.0466. Mol Ther. 2001. PMID: 11592835
-
Benefits of Neuronal Preferential Systemic Gene Therapy for Neurotransmitter Deficiency.Mol Ther. 2015 Oct;23(10):1572-81. doi: 10.1038/mt.2015.122. Epub 2015 Jul 3. Mol Ther. 2015. PMID: 26137853 Free PMC article.
-
AADC deficiency: occurring in humans, modeled in rodents.Adv Pharmacol. 2013;68:273-84. doi: 10.1016/B978-0-12-411512-5.00013-0. Adv Pharmacol. 2013. PMID: 24054149 Review.
-
Aromatic amino acid decarboxylase deficiency: Molecular and metabolic basis and therapeutic outlook.Mol Genet Metab. 2019 May;127(1):12-22. doi: 10.1016/j.ymgme.2019.03.009. Epub 2019 Mar 27. Mol Genet Metab. 2019. PMID: 30952622 Review.
Cited by
-
Case report: First case report of an Emirati child with a novel gene variant causing aromatic L-amino acid decarboxylase deficiency.Front Pediatr. 2022 Aug 30;10:964201. doi: 10.3389/fped.2022.964201. eCollection 2022. Front Pediatr. 2022. PMID: 36110109 Free PMC article.
-
Neurosurgical gene therapy for central nervous system diseases.Neurotherapeutics. 2024 Jul;21(4):e00434. doi: 10.1016/j.neurot.2024.e00434. Epub 2024 Aug 26. Neurotherapeutics. 2024. PMID: 39191071 Free PMC article. Review.
-
Gene therapy for neurotransmitter-related disorders.J Inherit Metab Dis. 2024 Jan;47(1):176-191. doi: 10.1002/jimd.12697. J Inherit Metab Dis. 2024. PMID: 38221762 Free PMC article. Review.
-
Identification of Potential Clusters of Signs and Symptoms to Prioritize Patients' Eligibility for AADCd Screening by 3-OMD Testing: An Italian Delphi Consensus.Behav Neurol. 2024 Apr 9;2024:1023861. doi: 10.1155/2024/1023861. eCollection 2024. Behav Neurol. 2024. PMID: 39280026 Free PMC article.
-
Design and Validation of a Multi-Point Injection Technology for MR-Guided Convection Enhanced Delivery in the Brain.Front Med Technol. 2021 Oct 14;3:725844. doi: 10.3389/fmedt.2021.725844. eCollection 2021. Front Med Technol. 2021. PMID: 35047955 Free PMC article.
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical